S. Korea Ministry Inspects Clinics Over Obesity Drug Rules

South Korea to Inspect Medical Facilities

South Korea's Ministry of Health and Welfare announced on Thursday its plan to conduct on-site inspections of medical institutions suspected of illegally selling self-injectable obesity drugs. These inspections will target facilities nationwide that are believed to be bypassing established regulations for prescribing and dispensing these medications.

The ministry's action follows an observed increase in cases where medical institutions are selling these drugs directly to patients without adhering to the required separation of prescription and dispensing processes, which is a key safeguard under the Pharmaceutical Affairs Act.

Regulatory Framework and Violations

Under South Korea's Pharmaceutical Affairs Act, self-injectable drugs, which are designed for patient self-administration, must be prescribed by a physician and then dispensed by a licensed pharmacist. An exception exists only when a physician directly administers the injection, for instance, to educate a patient on proper usage.

The Ministry of Health and Welfare has consistently informed medical facilities that direct on-site dispensing and sale are permissible solely under such specific patient education scenarios. However, the ministry noted a sharp rise in institutions selling these prescription drugs without performing the direct administration required by law.

Penalties and Enforcement Measures

Violations of the Pharmaceutical Affairs Act concerning the separation of prescribing and dispensing can result in severe penalties, including up to one year in prison or a fine of up to 10 million South Korean won, equivalent to approximately $7,557.

Furthermore, the Medical Service Act stipulates that failing to issue a proper prescription can lead to a 15-day suspension of a medical license for a first offense, escalating to a 30-day suspension for a second offense within a two-year period.

The ministry, in collaboration with local governments, plans to take legal action against any institutions found non-compliant during these inspections, while also continuing to monitor the supply of these drugs to individual facilities.

Implications for Professional Aesthetics in Korea

Kwak Soon-heon, Director General for health care policy at the Ministry of Health and Welfare, emphasized the need for stricter oversight as demand for self-injectable obesity drugs grows. He stated that this increasing demand must not lead to illegal sales that circumvent crucial safeguards for public health and drug misuse prevention.

For professional aesthetics clinics and practitioners in South Korea, this heightened enforcement means a renewed focus on strict adherence to pharmaceutical regulations.

Institutions must ensure their dispensing practices align precisely with legal requirements, particularly regarding the mandatory separation of prescribing and dispensing, to avoid significant legal and operational repercussions.